Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 5/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6811793 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MAPTMAPK1CES2CES1 | |
| SCHEMBL12317988 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MAPTMAPK1CES2CES1 | |
| SCHEMBL13983961 | 0.78 | CES2 (0.52) | ALDH1A1CES2CES1RAB9ANPC1 | |
| SCHEMBL2906532 | 0.77 | — | — | |
| SCHEMBL17134307 | 0.77 | — | — | |
| SCHEMBL10265221 | 0.76 | CES2 (0.44) | ALDH1A1MAPTMAPK1CES2CES1 | |
| SCHEMBL10205134 | 0.76 | CES2 (0.44) | ALDH1A1MAPTMAPK1CES2CES1 | |
| SCHEMBL22726445 | 0.76 | CES2 (0.44) | ALDH1A1CES2CES1RAB9ANPC1 | |
| SCHEMBL15932254 | 0.76 | CES2 (0.44) | ALDH1A1MAPTMAPK1CES2CES1 | |
| SCHEMBL9653590 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073359-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | MOLECULAR PROBES, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20160139135-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | LIFE TECHNOLOGIES CORP (US) | 2016-05-19 | — | — | US | disclosed |
| US-8865891-B2 | Optically-detectable enzyme substrates and their method of use | Life Technologies Corporation (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120329770-A1 | CEPHALOSPORIN DERIVATIVES USEFUL AS BETA-LACTAMASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | DMITRIENKO GARY IGOR (CA) | 2012-12-27 | — | — | US | disclosed |
| US-8168622-B2 | β-lactamase-resistant cephalosporin ester compounds and salts of thereof | ZHEJIANG YONGNING PHARMACEUTICAL CO., LTD. (CN) | 2012-05-01 | — | — | US | disclosed |
| US-8168622-B2 | β-lactamase-resistant cephalosporin ester compounds and salts of thereof | ZHEJIANG YONGNING PHARMACEUTICAL CO., LTD. (CN) | 2012-05-01 | — | — | US | disclosed |
| US-20120040897-A1 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2012-02-16 | — | — | US | disclosed |
| US-20120040897-A1 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2012-02-16 | — | — | US | disclosed |
| WO-2011103686-A1 | CEPHALOSPORIN DERIVATIVES USEFUL AS β-LACTAMASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | VISWANATHA , SUNDARAMMA (CA) | 2011-09-01 | — | — | WO | disclosed |
| US-20100227843-A1 | BETA-LACTAMASE-RESISTANT CEPHALOSPORIN ESTER COMPOUNDS AND SALTS OF THEREOF | ZHEJIANG YONGNING PHARMACEUTICAL FACTORY (CN) | 2010-09-09 | — | — | US | disclosed |
| US-20100227843-A1 | BETA-LACTAMASE-RESISTANT CEPHALOSPORIN ESTER COMPOUNDS AND SALTS OF THEREOF | ZHEJIANG YONGNING PHARMACEUTICAL FACTORY (CN) | 2010-09-09 | — | — | US | disclosed |
| US-7750148-B2 | Intermediate compound for the production of β-lactamase-resistant cephalosporin ester compounds and salts thereof | ZHEJIANG YONGNING PHARMACEUTICAL FACTORY (CN) | 2010-07-06 | — | — | US | disclosed |
| US-7750148-B2 | Intermediate compound for the production of β-lactamase-resistant cephalosporin ester compounds and salts thereof | ZHEJIANG YONGNING PHARMACEUTICAL FACTORY (CN) | 2010-07-06 | — | — | US | disclosed |
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
| US-20070134729-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070093464-A1 | Beta-lactamase resistant cephalosporin ester compounds and salts of thereof | ZHEJIANG YONGNING PHARMACEUTICAL CO., LTD. (CN) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070134729-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | ALDH1A1 2244/4885MAPT 3874/4885MAPK1 4374/4885 |
| US-20120040897-A1 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | NR1D2, STARD10, NR1D1 | ALDH1A1 3340/4885MAPT 1178/4885MAPK1 3366/4885 |
| US-20120329770-A1 | CEPHALOSPORIN DERIVATIVES USEFUL AS BETA-LACTAMASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CMBL, PEPD, BCHE | ALDH1A1 529/4885MAPT 4430/4885MAPK1 4779/4885 |
| US-20070093464-A1 | Beta-lactamase resistant cephalosporin ester compounds and salts of thereof | MGAM, NOTUM, STS | ALDH1A1 1052/4885MAPT 4462/4885MAPK1 4583/4885 |
| US-20160139135-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | MGAM, LCT, GAA | ALDH1A1 310/4885MAPT 2586/4885MAPK1 4586/4885 |
| US-20170073359-A1 | Optically-Detectable Enzyme Substrates and Their Method of Use | MGAM, LCT, GAA | ALDH1A1 310/4885MAPT 2586/4885MAPK1 4586/4885 |
| US-20100227843-A1 | BETA-LACTAMASE-RESISTANT CEPHALOSPORIN ESTER COMPOUNDS AND SALTS OF THEREOF | CEL, CES2, BCHE | ALDH1A1 464/4885MAPT 3540/4885MAPK1 4740/4885 |
| US-20070154948-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | ALDH1A1 2244/4885MAPT 3874/4885MAPK1 4374/4885 |
| US-20090111737-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | ALDH1A1 2244/4885MAPT 3874/4885MAPK1 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.